P/E ratio for Celldex Therapeutics (CLDX)
P/E ratio as of May 2024 (TTM): -16.4
According to Celldex Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.3958. At the end of 2022 the company had a P/E ratio of -18.6.
P/E ratio history for Celldex Therapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -18.6 | -20.85% |
| 2021 | -23.6 | 187.79% |
| 2020 | -8.19 | 1232.67% |
| 2019 | -0.6143 | 222.52% |
| 2018 | -0.1905 | -95.14% |
| 2017 | -3.92 | 39.62% |
| 2016 | -2.81 | -76.53% |
| 2015 | -12.0 | -13.43% |
| 2014 | -13.8 | -41.75% |
| 2013 | -23.7 | 260.8% |
| 2012 | -6.58 | 185.91% |
| 2011 | -2.30 | -95.53% |
| 2010 | -51.5 | 1993.62% |
| 2009 | -2.46 | 17.09% |
| 2008 | -2.10 | 660.49% |
| 2007 | -0.2762 | -32.18% |
| 2006 | -0.4073 | -94.8% |
| 2005 | -7.83 | -29.85% |
| 2004 | -11.2 | -18.49% |
| 2003 | -13.7 | 190.97% |
| 2002 | -4.71 | -54.21% |
| 2001 | -10.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 14.6 | -189.13% | 🇺🇸 USA |
 Amgen AMGN | 19.6 | -219.56% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 12.2 | -174.17% | 🇬🇧 UK |
 Titan Pharmaceuticals
TTNP | -11.8 | -28.31% | 🇺🇸 USA |
 Seagen
SGEN | -57.0 | 247.91% | 🇺🇸 USA |
 Agenus
AGEN | -15.6 | -4.85% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | -0.1598 | -99.03% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.